Tezampanel is an AMPA and kainate receptor antagonist that has been investigated as a therapeutic agent for conditions including acute and chronic pain, migraine, and opioid withdrawal syndrome. As a selective… Read more
Tezampanel is an AMPA and kainate receptor antagonist that has been investigated as a therapeutic agent for conditions including acute and chronic pain, migraine, and opioid withdrawal syndrome. As a selective competitive antagonist of ionotropic glutamate receptors, this compound functions by inhibiting excitatory synaptic transmission in the central nervous system. In pharmaceutical research and development, high-quality analytical standards are essential for characterizing this drug and its degradation pathways. This category provides access to critical tools such as impurities, metabolites, and stable isotope labelled compounds required for comprehensive impurity profiling and rigorous method validation. Pharmaceutical laboratories rely on these reference standards to ensure accuracy in analytical testing and to maintain stringent quality control throughout the drug development lifecycle. These materials facilitate precise quantification and identification, supporting researchers as they evaluate the safety and efficacy of the molecule in various preclinical and clinical models.